A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have lost about 0.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Vertex due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates flatlined during the past month.
VGM Scores
Currently, Vertex has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Vertex has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Vertex belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Agios Pharmaceuticals (AGIO), has gained 17.8% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.
Agios Pharmaceuticals reported revenues of $8.73 million in the last reported quarter, representing a year-over-year change of +6.6%. EPS of -$1.55 for the same period compares with -$1.45 a year ago.
Agios Pharmaceuticals is expected to post a loss of $1.74 per share for the current quarter, representing a year-over-year change of -3%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.6%.
Agios Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
